@lancerinvesting There is too much uncertainty right now. Where do interest rates go? What happens with Iran? How much of the selloff is liquidation to fund the new giant IPOs. Nationwide resistance to AI and data centers? Political uncertainty across the country? Etc
@lancerinvesting It’s a great time to start a position in $HOOD. It’s got several money making products and looks to be starting another run. Morningstar highlighted its momentum in net deposit growth and expressed optimism about its credit card program and prediction market joint venture.
@lancerinvesting I’m definitely interested above the 200 DMA. As gas prices come down more people will have confidence in the market and all the other products $HOOD has and they will be back to $120 before the end of the year.
@lancerinvesting They need to do a stock split. Maybe 15:1 so the price would be $200. There’s nothing sexy about owning 3 shares at $3,000 but 45-50 shares at $200 gets my attention. Then I can add slowly on pullbacks and feel good about it.
@lancerinvesting If a new Fed Chairman brings a little interest rate relief and gas prices begin to fade we could see a rally in $TM It’s oversold and has a nice dividend
@lancerinvesting Eli Lilly $LLYsoared 9.5% after reporting strong sales for its GLP-1 drugs Zepbound and Mounjaro.
Zepbound revenue increased 80% year over year to $4.16 billion and Mounjaro revenue soared 125% to $8.66 billion.
@lancerinvesting Despite lower prices for Zepbound and Mounjaro, strong demand helped lift Lilly’s overall revenue 56% year over year to $19.7 billion, meaning GLP-1s accounted for roughly two-thirds of Eli Lilly’s total sales.
@lancerinvesting $CAT Caterpiller soared 10% today after strong Q1 earnings that beat estimates and raised 2026 sales growth outlook. It is now +55% Year to Date